ストックスクリーナーアプリを入手
18.11
0.44%
0.08
アフターアワーズ：
18.13
0.02
+0.11%
前日終値:
$18.03
開ける：
$17.98
24時間の取引高:
2.52M
Relative Volume:
0.87
時価総額：
$57.21B
収益：
$29.85B
当期純損益:
$776.90M
株価収益率:
75.21
EPS:
0.2408
ネットキャッシュフロー:
$4.35B
1週間 パフォーマンス:
+1.91%
1か月 パフォーマンス:
-2.95%
6か月 パフォーマンス:
+20.25%
1年 パフォーマンス:
+19.70%
1日の値動き範囲:
$17.98
$18.20
1週間の範囲:
$17.74
$18.52
52週間の値動き範囲:
$12.99
$18.82
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK vs ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-13 | 再開されました | Morgan Stanley | Overweight |
| 2025-04-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-07-19 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-10-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-01 | 開始されました | Cowen | Market Perform |
| 2019-08-15 | ダウングレード | Daiwa Securities | Outperform → Neutral |
すべてを表示
Takeda Pharmaceutical Co Adr (TAK) 最新ニュース
Takeda Pharmaceutical (ADR) Stock Steady Amid Pharma Sector Volatility as Investors Eye Pipeline Pro - AD HOC NEWS
Takeda Pharmaceutical Co Ltd (HAM:TKDA)Valuation Measures & Financial Statistics - GuruFocus
Feiba VH (Takeda Pharmaceuticals) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, & Forecasts, 2020-2025, 2025-2030F, 2035F - GlobeNewswire Inc.
FDA Grants Priority Review for Takeda (TAK) and Protagonist's Rusfertide in PV Treatment - Finviz
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Takeda Stock: Quiet Japan Pharma With a Big U.S. Pipeline Bet - AD HOC NEWS
Takeda Stock: Quiet Pharma Giant That US Investors Keep Missing - AD HOC NEWS
Takeda Pharmaceutical ADR sees IBD RS rating climb to 76 - MSN
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? - Finviz
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Earnings call transcript: Takeda beats Q3 2025 forecasts, stock climbs - Investing.com
Takeda Pharmaceutical ADR: Defensive Pharma Giant Tests Investor Patience as Shares Drift Near Lows - AD HOC NEWS
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? - Finviz
Argenx SE – ADR (ARGX) Sentiments Bolstered on Vyvgart FDA Priority Review Milestone - Yahoo Finance
Takeda Pharma ADR earnings beat by $0.04, revenue topped estimates - Investing.com Australia
Stocks To Watch: Takeda Pharmaceutical ADR Sees Relative Strength Rating Rise To 83 - Investor's Business Daily
Takeda Q3 FY2025 slides: Revenue dips 3.3% as company preps key 2026 launches - Investing.com
Earnings call transcript: Takeda Pharma Q3 2026 sees mixed performance - Investing.com
Apple, Visa, KLA-Tencor and more set to report earnings Thursday By Investing.com - Investing.com Nigeria
Takeda Pharmaceutical ADR Gets Technical Rating Upgrade - Investor's Business Daily
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
US earnings seasonQ4 2025 - Interactive Investor
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? - Finviz
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - Finviz
Takeda Pharmaceutical ADR Sees IBD RS Rating Climb To 76 - Investor's Business Daily
Book value per share of Takeda Pharmaceutical Co. Ltd. Sponsored ADR – GETTEX:TKDA - TradingView — Track All Markets
The Truth About Takeda Pharmaceutical Co Ltd: Is This Pharma Giant a Hidden Power Play for Your Port - AD HOC NEWS
G-Protein Coupled Receptors (GPCRs) Market Size to Hit USD 6.04 Billion by 2032, Growing at a CAGR of 5.59% - GlobeNewswire Inc.
Ethic Inc. Buys 43,295 Shares of Takeda Pharmaceutical Co. $TAK - Defense World
Takeda Pharmaceutical (NYSE:TAK) Strengthens Position in Healthcare - Kalkine Media
Takeda Pharmaceutical Co Ltd (TAK) Bonds - GuruFocus
Takeda Pharmaceutical Co Ltd ADR Stock Price Today | NYSE: TAK Live - Investing.com
Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - GlobeNewswire Inc.
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz
INNOVENT BIO Completes Introduction of Takeda, Raising ~HKD780M Net - AASTOCKS.com
TAK vs. DSNKY: Which Stock Is the Better Value Option? - MSN
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Takeda Pharmaceutical Co Adr (TAK) 財務データ
収益
当期純利益
現金流量
EPS
1.16%
大文字化:
|
ボリューム (24 時間):